Circulating Tumor DNA Clearance Predicts Better Outcomes with Perioperative Nivolumab in Lung Cancer
Analyses from the phase III CheckMate 77T study indicate that clearance of circulating tumor DNA before surgery is linked to improved clinical outcomes when nivolumab is used perioperatively in non-small-cell lung cancer. This biomarker could help guide treatment decisions and patient selection.
Related stories
Sugar Restriction in Infancy Tied to Lower Cancer Risk; Melanoma Vaccine Shows Promise · Cancer research
New evidence may settle prostate cancer focal therapy debate · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Biomarkers that predict improved outcomes after perioperative immune-based therapy for lung cancer.” Browse more stories.